[1] TAKAHASHI K, YAMANAKA S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.
[2] TAKAHASHI K, TANABE K, OHNUKI M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-872.
[3] YU J, VODYANIK MA, SMUGA-OTTO K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858): 1917-1920.
[4] RAJESH D, DICKERSON SJ, YU J, et al. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood. 2011;118(7):1797-1800.
[5] HU K, YU J, SUKNUNTHA K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood. 2011;117(14):e109-119.
[6] TAKAHASHI K, YAMANAKA S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17(3): 183-193.
[7] VAN LAAKE LW, QIAN L, CHENG P, et al. Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circ Res. 2010;107(3):340-347.
[8] ARAKI R, UDA M, HOKI Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013;494(7435):100-104.
[9] GUHA P, MORGAN JW, MOSTOSLAVSKY G, et al. Lack of Immune Response to Differentiated Cells Derived from Syngeneic Induced Pluripotent Stem Cells. Cell Stem Cell. 2017;21(1):144-148.
[10] YOSHIHARA M, HAYASHIZAKI Y, MURAKAWA Y. Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications. Stem Cell Rev Rep. 2017;13(1):7-16.
[11] CYRANOSKI D. Japanese woman is first recipient of next generation stem cells. Nature. 2014;12.
[12] CHAKRADHAR S. An eye to the future: Researchers debate best path for stem cell-derived therapies. Nat Med. 2016;22(2):116-119.
[13] GARBER K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol. 2015;33(9):890-891.
[14] YAN Y, JIANG J, ZHANG M, et al. Effect of iPSCs-derived keratinocytes on healing of full-thickness skin wounds in mice. Exp Cell Res. 2019;385(1): 111627.
[15] CHEN X, SONG XH, YIN Z, et al. Stepwise differentiation of human embryonic stem cells promotes tendon regeneration by secreting fetal tendon matrix and differentiation factors. Stem Cells. 2009;27(6): 1276-1287.
[16] NI M, LUI PP, RUI YF, et al. Tendon-derived stem cells (TDSCs) promote tendon repair in a rat patellar tendon window defect model. J Orthop Res. 2012;30(4):613-619.
[17] XU W, WANG Y, LIU E, et al. Human iPSC-derived neural crest stem cells promote tendon repair in a rat patellar tendon window defect model. Tissue Eng Part A. 2013;19(21-22):2439-2451.
[18] BOHÁČ M, CSÖBÖNYEIOVÁ M, KUPCOVÁ I, et al. Stem cell regenerative potential for plastic and reconstructive surgery. Cell Tissue Bank. 2016; 17(4):735-744.
[19] KOUROUPIS D, KYRKOU A, TRIANTAFYLLIDI E, et al. Generation of stem cell-based bioartificial anterior cruciate ligament (ACL) grafts for effective ACL rupture repair. Stem Cell Res. 2016;17(2):448-457.
[20] NAGY K, SUNG HK, ZHANG P, et al. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev Rep. 2011;7(3):693-702.
[21] KOMURA S, SATAKE T, GOTO A, et al. Induced pluripotent stem cell-derived tenocyte-like cells promote the regeneration of injured tendons in mice. Sci Rep. 2020;10(1):3992.
[22] BAVIN EP, SMITH O, BAIRD AE, et al. Equine Induced Pluripotent Stem Cells have a Reduced Tendon Differentiation Capacity Compared to Embryonic Stem Cells. Front Vet Sci. 2015;2:55.
[23] BAUER TW, MUSCHLER GF. Bone graft materials. An overview of the basic science. Clin Orthop Relat Res. 2000;(371):10-27.
[24] LAURENCIN C, KHAN Y, EL-AMIN SF. Bone graft substitutes. Expert Rev Med Devices. 2006;3(1):49-57.
[25] MENDES SC, TIBBE JM, VEENHOF M, et al. Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. Tissue Eng. 2002;8(6):911-920.
[26] STENDERUP K, JUSTESEN J, CLAUSEN C, et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919-926.
[27] RODRÍGUEZ JP, MONTECINOS L, RÍOS S, et al. Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem. 2000;79(4):557-565.
[28] YAMANAKA S. Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors. Cell Prolif. 2008;41 Suppl 1 (Suppl 1):51-56.
[29] JUNG Y, BAUER G, NOLTA JA. Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells. 2012;30(1):42-47.
[30] YE JH, XU YJ, GAO J, et al. Critical-size calvarial bone defects healing in a mouse model with silk scaffolds and SATB2-modified iPSCs. Biomaterials. 2011;32(22):5065-5076.
[31] TANG M, CHEN W, LIU J, et al. Human induced pluripotent stem cell-derived mesenchymal stem cell seeding on calcium phosphate scaffold for bone regeneration. Tissue Eng Part A. 2014 ;20(7-8):1295-1305.
[32] LIU J, CHEN W, ZHAO Z, et al. Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering. Biomaterials. 2013;34(32):7862-7872.
[33] KANG H, SHIH YR, NAKASAKI M, et al. Small molecule-driven direct conversion of human pluripotent stem cells into functional osteoblasts. Sci Adv. 2016 ;2(8):e1600691.
[34] BASTAMI F, NAZEMAN P, MOSLEMI H, et al. Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review. Cell Prolif. 2017;50(2):e12321.
[35] RANA D, KUMAR S, WEBSTER TJ, et al. Impact of Induced Pluripotent Stem Cells in Bone Repair and Regeneration. Curr Osteoporos Rep. 2019;17(4):226-234.
[36] MA VY, CHAN L, CARRUTHERS KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986-995.
[37] LIN W, CHEN M, HU C, et al. Endowing iPSC-Derived MSCs with Angiogenic and Keratinogenic Differentiation Potential: A Promising Cell Source for Skin Tissue Engineering. Biomed Res Int. 2018;2018: 8459503.
[38] OCHS BG, MÜLLER-HORVAT C, ALBRECHT D, et al. Remodeling of articular cartilage and subchondral bone after bone grafting and matrix-associated autologous chondrocyte implantation for osteochondritis dissecans of the knee. Am J Sports Med. 2011;39(4):764-773.
[39] VISTE A, PIPERNO M, DESMARCHELIER R, et al. Autologous chondrocyte implantation for traumatic full-thickness cartilage defects of the knee in 14 patients: 6-year functional outcomes. Orthop Traumatol Surg Res. 2012;98(7):737-743.
[40] ZHANG Z, ZHONG X, JI H, et al. Matrix-induced autologous chondrocyte implantation for the treatment of chondral defects of the knees in Chinese patients. Drug Des Devel Ther. 2014;8:2439-2448.
[41] UTO S, NISHIZAWA S, TAKASAWA Y, et al. Bone and cartilage repair by transplantation of induced pluripotent stem cells in murine joint defect model. Biomed Res. 2013;34(6):281-288.
[42] KO JY, KIM KI, PARK S, et al. In vitro chondrogenesis and in vivo repair of osteochondral defect with human induced pluripotent stem cells. Biomaterials. 2014;35(11):3571-3581.
[43] HONTANI K, ONODERA T, TERASHIMA M, et al. Chondrogenic differentiation of mouse induced pluripotent stem cells using the three-dimensional culture with ultra-purified alginate gel. J Biomed Mater Res A. 2019;107(5):1086-1093.
[44] ZHU Y, WU X, LIANG Y, et al. Repair of cartilage defects in osteoarthritis rats with induced pluripotent stem cell derived chondrocytes. BMC Biotechnol. 2016;16(1):78.
[45] DIEDERICHS S, GABLER J, AUTENRIETH J, et al. Differential Regulation of SOX9 Protein During Chondrogenesis of Induced Pluripotent Stem Cells Versus Mesenchymal Stromal Cells: A Shortcoming for Cartilage Formation. Stem Cells Dev. 2016;25(8):598-609.
[46] YAMASHITA A, MORIOKA M, YAHARA Y, et al. Generation of scaffoldless hyaline cartilaginous tissue from human iPSCs. Stem Cell Reports. 2015; 4(3):404-418.
[47] ZHOU X, SHI G, FAN B, et al. Polycaprolactone electrospun fiber scaffold loaded with iPSCs-NSCs and ASCs as a novel tissue engineering scaffold for the treatment of spinal cord injury. Int J Nanomedicine. 2018;13:6265-6277.
[48] KUBINOVA S, MURALI R, SYKOVA E, et al. A Comparative Study of Three Different Types of Stem Cells for Treatment of Rat Spinal Cord Injury. Cell Transplant. 2017;26(4):585-603.
[49] NAGOSHI N, OKANO H. iPSC-derived neural precursor cells: potential for cell transplantation therapy in spinal cord injury. Cell Mol Life Sci. 2018;75(6):989-1000.
[50] HUANG Y, ZHANG XF, GAO G, et al. 3D bioprinting and the current applications in tissue engineering. Biotechnol J. 2017;12(8):1600734.
|